Biocon moves up on securing supply contract for Pertuzumab in Brazil
Biocon is currently trading at Rs. 395.90, up by 2.40 points or 0.61% from its previous closing of Rs. 393.50 on the BSE.
The scrip opened at Rs. 391.10 and has touched a high and low of Rs. 399.50 and Rs. 391.10 respectively. So far 3987 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 447.00 on 16-Jul-2026 and a 52 week low of Rs. 337.20 on 30-Sep-2025.
Last one week high and low of the scrip stood at Rs. 405.70 and Rs. 388.70 respectively. The current market cap of the company is Rs. 63737.34 crore.
The promoters holding in the company stood at 44.68%, while Institutions and Non-Institutions held 31.52% and 23.80% respectively.
Biocon has signed partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s Productive Development Partnership (PDP) program.
The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab. The PDP provides the consortium exclusive access to Brazil’s public healthcare market, which accounts for approximately 70% of the country’s demand for Pertuzumab. It also supports the long-term adoption of Biocon’s product within Brazil’s public oncology network.
Biocon will receive payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.
